Journal article
Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial
AJ Wade, JS Doyle, E Gane, C Stedman, B Draper, D Iser, SK Roberts, W Kemp, D Petrie, N Scott, P Higgs, PA Agius, J Roney, L Stothers, AJ Thompson, ME Hellard
Trials | BMC | Published : 2018
Abstract
Background: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to treatment. Direct-acting antiviral (DAA) treatment can be provided in primary healthcare services (PHCS), improving accessibility, and, potentially, retention in care. Here, we describe our protocol for assessing the effectiveness of providing DAAs in PHCS, and the impact on the HCV care cascade. In addition, we reflect on the challenges of conducting a model of care study during a period of unprecedented change in HCV care and treatment. Methods: Consenting patients with HCV infection attending 13 PHCS in Australia or New Zealand are randomized to receive D..
View full abstractGrants
Funding Acknowledgements
The Prime Study is an investigator-initiated study funded by AbbVie. The investigators are responsible for the study design, data collection and analysis, interpretation of data and preparation of manuscripts. .